Volume : 12, Issue : 10, October – 2025
Title:
CURRENT REGULATIONS FOR CLINICAL TRIALS
Authors :
Yaradla Charitha *, Dr V Swapna, Dr. D. Varun.
Abstract :
Regulatory process, by which a person/organization/sponsor/innovator gets authorization to launch a drug in the market, is known as drug approval process. In general, a drug approval process comprises of various stages: application to conduct clinical trials, conducting clinical trials, application to marketing authorization of drug and post-marketing studies. Every country has its own regulatory authority, which is responsible to enforce the rules and regulations and issue the guidelines to regulate the marketing of the drugs. This work focuses on the drug approval process in India and USA.
Keywords: Drug approval process, Clinical trials, marketing.
Cite This Article:
Please cite this article in press Yaradla Charitha et al., Current Regulations For Clinical Trials , Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. Planning commission of india. 2006. Report of the working group for drugs and pharmaceuticals for eleventh five-year plan (website: www.planningcommission.nic.in)
2. Schuchman, miriam. 2007. ‘commercializing clinical trials: risks and benefits of the cro boom’. New england journal of medicine. October 4.
3. Pacific bridge. 2007. ‘medical device marketing situation in india.’
4. Gehl sampath, padmashree. 2008. ‘india’s pharmaceutical sector in 2008. Emerging strategies and global and local implications for access to medicines’.
5. Oppi. 2008. Indian pharmaceutical industry: vision 2015.
6. Singh, seema. 2007. ‘indian pharma enters the global arena’. Cell. 128 march 9. Elsevier.
7. Das, anjan & kumar, subodh. 2008. ‘innovation, ipr and public good’. Express pharma pulse. 16-31 december, 2008.
8. Ficci. 2005. White paper on ‘clinical trials in india’.
9. Srivastava, d. 2008. ‘a country level report on the pharmaceutical sector in india’. Report commissioned by dfid, uk
10. Central drugs standards control organization. (website: www.cdsco.nic.in).
11. Horner a., comparison of a global submission of new biological entity and a new chemical entity – strategic decisions and criteria for implementation (2005) http://www.dra.uni-bonn.de/hoerner. (assessed on march 09th 2010).
12. Samantha Cruz Rivera, Xiaoxuan Liu, An-Wen Chan, Alastair K Denniston, Melanie J Calvert. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Lancet Digital Health 2020; 2: e549–560.
13. Xiaoxuan Liu, Samantha Cruz Rivera, David Moher, Melanie J Calvert, Alastair K Denniston. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Lancet Digital Health 2020; 2: e537–548.
14. Z.F. Udwadia, P. Singh, H. Barkate. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. International Journal of Infectious Diseases 103 (2021) 62–71